Clinical Trial Update: Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of docetaxel and irinotecan (DI) for recurrent or refractory bone and soft tissue sarcomas; the current status is unk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Sarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Sarcoma | Phase 2 | Status: UNKNOWN